Amedeo Smart

Free Medical Literature Service

 

Amedeo

Breast Cancer
  Free Subscription

Articles published in
J Nucl Med
    April 2024
  1. MOSER R, Pfeiffer S, Cala L, Klein E, et al
    Detecting Metastatic Patterns of Oligometastatic Breast Cancer: A Comparative Analysis of (18)F-FDG PET/CT and Conventional CT Imaging.
    J Nucl Med. 2024 Apr 18:jnumed.123.266925. doi: 10.2967/jnumed.123.266925.
    >> Share

  2. GEBHART G, Keyaerts M, Guiot T, Flamen P, et al
    Optimal [(18)F]FDG PET/CT Cutoff for Pathologic Complete Response in HER2-Positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERGain Trial.
    J Nucl Med. 2024 Apr 4:jnumed.123.266384. doi: 10.2967/jnumed.123.266384.
    >> Share

    March 2024
  3. ALTENA R, Buren SA, Blomgren A, Karlsson E, et al
    Human Epidermal Growth Factor Receptor 2 (HER2) PET Imaging of HER2-Low Breast Cancer with [(68)Ga]Ga-ABY-025: Results from a Pilot Study.
    J Nucl Med. 2024 Mar 28:jnumed.123.266847. doi: 10.2967/jnumed.123.266847.
    >> Share

  4. SAHIN E, Kus T, Aytekin A, Uzun E, et al
    (68)Ga-FAPI PET/CT as an Alternative to (18)F-FDG PET/CT in the Imaging of Invasive Lobular Breast Carcinoma.
    J Nucl Med. 2024 Mar 14:jnumed.123.266798. doi: 10.2967/jnumed.123.266798.
    >> Share

    February 2024
  5. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
    Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
    J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
    >> Share

  6. GEBHART G, Piccart M, Mankoff D
    Molecular Imaging in Breast Cancer: Martine Piccart and Geraldine Gebhart Talk with David Mankoff About 2 Generations of Research.
    J Nucl Med. 2024 Feb 8:jnumed.124.267461. doi: 10.2967/jnumed.124.267461.
    >> Share

  7. JACENE H, Dietsche E, Specht J
    The Current and Future Roles of Precision Oncology in Advanced Breast Cancer.
    J Nucl Med. 2024 Feb 1:jnumed.122.264882. doi: 10.2967/jnumed.122.264882.
    >> Share

  8. GONDRY O, Caveliers V, Xavier C, Raes L, et al
    Phase II Trial Assessing the Repeatability and Tumor Uptake of [(68)Ga]Ga-HER2 Single-Domain Antibody PET/CT in Patients with Breast Carcinoma.
    J Nucl Med. 2024;65:178-184.
    >> Share

    January 2024
  9. YEH R, O'Donoghue JA, Jayaprakasam VS, Mauguen A, et al
    First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer.
    J Nucl Med. 2024 Jan 25:jnumed.123.266392. doi: 10.2967/jnumed.123.266392.
    >> Share

    December 2023
  10. MANKOFF D, Balogova S, Dunnwald L, Dehdashti F, et al
    Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16alpha-[(18)F]Fluoro-17beta-Estradiol PET.
    J Nucl Med. 2023 Dec 7:jnumed.123.266938. doi: 10.2967/jnumed.123.266938.
    >> Share

    November 2023
  11. CHEN L, Zheng S, Chen L, Xu S, et al
    (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study.
    J Nucl Med. 2023 Nov 2:jnumed.123.266079. doi: 10.2967/jnumed.123.266079.
    >> Share

  12. GEBHART G
    (18)F-FDG PET "Metabolic Response" to Neoadjuvant Systemic Therapy for Breast Cancer: Quo Vadis?
    J Nucl Med. 2023;64:1697-1698.
    >> Share

    September 2023
  13. ALTENA R, Af Buren S, Tran T, Axelsson R, et al
    HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266101. doi: 10.2967/jnumed.123.266101.
    >> Share

  14. SEBAN RD
    Reply to: HER2-Low Breast Cancer Can Be Visualized by HER2 PET.
    J Nucl Med. 2023 Sep 14:jnumed.123.266490. doi: 10.2967/jnumed.123.266490.
    >> Share

    August 2023
  15. HENNESSY MA, Leal JP, Huang CY, Solnes LB, et al
    Correlation of SUV on Early Interim PET with Recurrence-Free Survival and Overall Survival in Primary Operable HER2-Positive Breast Cancer (the TBCRC026 Trial).
    J Nucl Med. 2023 Aug 31:jnumed.123.265853. doi: 10.2967/jnumed.123.265853.
    >> Share

  16. MOHR P, van Sluis J, Providencia L, van Snick JH, et al
    Long Versus Short Axial Field of View Immuno-PET/CT: Semiquantitative Evaluation for (89)Zr-Trastuzumab.
    J Nucl Med. 2023 Aug 3:jnumed.123.265621. doi: 10.2967/jnumed.123.265621.
    >> Share

    July 2023
  17. ALHUSEINALKHUDHUR A, Lindman H, Liss P, Sundin T, et al
    Human Epidermal Growth Factor Receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET/CT Predicts Early Metabolic Response in Metastatic Breast Cancer.
    J Nucl Med. 2023 Jul 13:jnumed.122.265364. doi: 10.2967/jnumed.122.265364.
    >> Share

    June 2023
  18. BROWN EL, Shmuel S, Mandleywala K, Panikar SS, et al
    Immuno-PET Detects Antibody-Drug Potency on Coadministration with Statins.
    J Nucl Med. 2023 Jun 29:jnumed.122.265172. doi: 10.2967/jnumed.122.265172.
    >> Share

  19. WATABE T, Naka S, Tatsumi M, Kamiya T, et al
    Initial Evaluation of [(18)F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions.
    J Nucl Med. 2023 Jun 2:jnumed.123.265486. doi: 10.2967/jnumed.123.265486.
    >> Share

    May 2023
  20. SEBAN RD, Champion L, Bellesoeur A, Vincent-Salomon A, et al
    Clinical Potential of HER2 PET as a Predictive Biomarker to Guide the Use of Trastuzumab Deruxtecan in Breast Cancer Patients.
    J Nucl Med. 2023 May 25:265434. doi: 10.2967/jnumed.123.265434.
    >> Share

    April 2023
  21. DONOHOE KJ, Carroll BJ, Chung DKV, Dibble EH, et al
    Summary: Appropriate Use Criteria for Lymphoscintigraphy in Sentinel Node Mapping and Lymphedema/Lipedema.
    J Nucl Med. 2023;64:525-528.
    >> Share

    March 2023
  22. ULANER GA, Mankoff DA, Clark AS, Fowler AM, et al
    Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16alpha-(18)F-Fluoro-17beta-Fluoroestradiol.
    J Nucl Med. 2023;64:351-354.
    >> Share

    January 2023
  23. FENG Y, Meshaw R, Zhao XG, Jannetti S, et al
    Effective Treatment of Human Breast Carcinoma Xenografts with Single-Dose (211)At-Labeled Anti-HER2 Single-Domain Antibody Fragment.
    J Nucl Med. 2023;64:124-130.
    >> Share

    November 2022
  24. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    >> Share

  25. BACKHAUS P, Burg MC, Asmus I, Pixberg M, et al
    Initial Results of FAPI-PET/MRI to Assess Response to Neoadjuvant Chemotherapy in Breast Cancer.
    J Nucl Med. 2022 Nov 17. pii: jnumed.122.264871. doi: 10.2967/jnumed.122.264871.
    >> Share

    October 2022
  26. VOGSEN M, Harbo F, Jakobsen NM, Nissen HJ, et al
    Response monitoring in metastatic breast cancer - a prospective study comparing (18)F-FDG PET/CT with conventional CT.
    J Nucl Med. 2022 Oct 7. pii: jnumed.121.263358. doi: 10.2967/jnumed.121.263358.
    >> Share

    September 2022
  27. MORAWITZ J, Sigl B, Rubbert C, Bruckmann NM, et al
    Clinical decision support for axillary lymph node staging in newly diagnosed breast cancer patients based on (18)F-FDG PET/MRI and machine-learning.
    J Nucl Med. 2022 Sep 22. pii: jnumed.122.264138. doi: 10.2967/jnumed.122.264138.
    >> Share

    August 2022
  28. SHIN J, Parker MFL, Zhu I, Alanizi A, et al
    Antigen-dependent inducible T cell reporter system for PET imaging of breast cancer and glioblastoma.
    J Nucl Med. 2022 Aug 18. pii: jnumed.122.264284. doi: 10.2967/jnumed.122.264284.
    >> Share

  29. SINGARAVELU I, Spitz H, Mahoney M, Dong Z, et al
    Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers to (18)F-FDG.
    J Nucl Med. 2022;63:1177-1183.
    >> Share

    June 2022
  30. ZHOU R, Choi H, Cao J, Pantel A, et al
    (18)F-Fluciclovine PET Imaging of Glutaminase Inhibition in Breast Cancer Models.
    J Nucl Med. 2022 Jun 30. pii: jnumed.122.264152. doi: 10.2967/jnumed.122.264152.
    >> Share

    May 2022
  31. OKAZAWA H
    ER Imaging for Estrogen-Related Tumors Is Bothersome but Useful.
    J Nucl Med. 2022;63:700-701.
    >> Share

    December 2021
  32. SEBAN RD, Richard C, Nascimento-Leite C, Ghidaglia J, et al
    Absolute lymphocyte count after COVID-19 vaccination is associated with vaccine-induced hypermetabolic lymph nodes on (18)F-FDG PET/CT: a focus in breast cancer care.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.263082. doi: 10.2967/jnumed.121.263082.
    >> Share

  33. MORTIMER JE, Bading JR, Frankel PH, Caroll M, et al
    Use of (64)Cu-DOTA-Trastuzumab PET to Predict Response and Outcome of Patients Receiving Trastuzumab Emtansine (T-DM1) for Metastatic Breast Cancer: A Pilot Study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262940. doi: 10.2967/jnumed.121.262940.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016